References

1. Almac Discovery.  ALM201 – Orphan Drug Designation Granted in Ovarian Cancer. Accessed on 17/03/2021. Modified on 17/03/2021. almacgroup.com, https://www.almacgroup.com/news/almac-discovery-is-granted-orphan-drug-designation-for-alm201-programme-in-ovarian-cancer/

2. Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L, Harley I et al.. (2020) FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. Br J Cancer, 122 (3): 361-371. [PMID:31772325]

3. McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F, Short A et al.. (2019) FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer, 19 (1): 351. [PMID:30975104]

4. McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A et al.. (2013) Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin Cancer Res, 19 (14): 3881-93. [PMID:23741069]

5. Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H et al.. (2011) FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res, 17 (5): 1044-56. [PMID:21364036]